ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 这是一项非随机自然史非治疗研究，将在美国和加拿大的约50个研究中心招募共计800例受试者，包括200例正常对照、400例MCI患者和200例轻度AD受试者，进行纵向随访。每个研究中心的目标是招募8例轻度认知障碍受试者、4例阿尔茨海默病受试者和4例健康老年对照受试者。 ADNI的主要目标是：1。制定改进的方法， 用于获取阿尔茨海默病（AD）、轻度认知障碍（MCI）患者和老年对照的纵向、多部位MRI和PET数据的标准。 2.获取一个可普遍访问的数据库，描述大脑结构和新陈代谢的纵向变化。同时，获取临床认知和生物标志物数据，以验证成像替代品。 3.在涉及这些患者的试验中，开发能够提供最大功效以确定治疗效果的方法。 4.根据统计分析章节中概述的临床和生物标志物数据检验一系列假设。 假设： A.2.假设检验 这一举措的主要目标是收集数据，而不是分析数据。除了开展临床活动外，我们还将根据临床和生物标志物数据测试几种假设。下面列举了一些例子： 1.从MCI到AD的转化率平均为10-15%/年。 2.逻辑记忆和载脂蛋白E（APOE）A14（APOE 4）状态的基线评分将预测从MCI到AD的转换。 3.全球功能的措施，如日常生活活动将比神经心理学措施更敏感，预测从MCI转换为AD。 4.从MCI到正常的回交率将非常低， 人口 5.血浆异前列腺素a）与疾病严重程度相关，B）较高的水平将预示着更快的下降速度。 6.海马体积和后扣带回葡萄糖代谢率可预测MCI向AD的下降和转化率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a non-randomized natural history non-treatment study in which a total of 800 subjects including 200 normal controls, 400 individuals with MCI, and 200 subjects with mild AD will be recruited at approximately 50 sites in the United States and Canada for longitudinal follow up. Each site's goal will be to recruit 8 subjects with Mild Cognitive Impairment, 4 subjects with Alzheimer's disease and 4 Healthy Elderly Controls. The major goals of the ADNI are to: 1. Develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and elderly controls. 2. Acquire a generally accessible data repository which describes longitudinal changes in brain structure and metabolism. In parallel, acquire clinical cognitive and biomarker data for validation of imaging surrogates. 3. Develop methods which will provide maximum power to determine treatment effects in trials involving these patients. 4. Test a series of hypotheses based on the clinical and biomarker data as outlined in the statistical analysis section. Hypothesis: A.2. HYPOTHESIS TESTING The major goal of this initiative is the collection of data rather than its analysis. In addition to carrying out the clinical initiative, we will test several hypotheses based on the clinical and biomarker data. A few examples are listed below: 1. Rates of conversion from MCI to AD will average 10-15%/year. 2. Baseline scores on logical memory and apolipoprotein E (APOE) epsilon 4 (APOE4) status will predict conversion from MCI to AD. 3. Measures of global functioning such as activities of everyday living will be more sensitive than neuropsychological measures for predicting conversion from MCI to AD. 4. The rate of backcrossing from MCI to normal will be extremely low for this population. 5. Plasma isoprostanes will a) be related to disease severity and b) higher levels will predict a faster rate of decline. 6. Hippocampal volume and posterior cingulate glucose metabolic rate will predict rate of decline and conversion from MCI to AD.